Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 2 results out of 2
Data Insights
Dalfampridine IR by Solaxa for Spinocerebellar Ataxia (SCA): Likelihood of Approval
Dalfampridine IR is under clinical development by Solaxa and currently in Phase II for Spinocerebellar Ataxia (SCA). According to GlobalData,...
Data Insights
Dalfampridine ER by Solaxa for Episodic Ataxia Type 2: Likelihood of Approval
Dalfampridine ER is under clinical development by Solaxa and currently in Phase II for Episodic Ataxia Type 2. According to...